← All trials
NCT06273930
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2024
- Primary completion
- Oct 15, 2024
- Completion date
- Oct 30, 2024
- First posted
- Feb 23, 2024
- Last posted
- Feb 23, 2024
- Enrollment
- 87
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of PakistanLead sponsor
- Government of PakistanOfficial
- Government of PakistanSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.